This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| AOD-9604 | Tesofensine | |
|---|---|---|
| Highest evidence tier on the page | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not approved for human use | Not approved for human use |
| Research area | Metabolic and incretin | Metabolic and incretin |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C78H123N23O23S2 | C17H23Cl2NO free base; C23H31Cl2NO8 as the 1:1 citrate salt used in the clinical tablets |
| Molar mass | 1815.1 g/mol for the disulfide-cyclised form. The reduced linear form is about 1817.1, which vendor certificates sometimes quote instead. | 328.3 g/mol free base; 520.4 g/mol citrate salt |
| CAS number | 221231-10-3 | 195875-84-4 free base; 195875-86-6 citrate |
| Registered trials on this site | 3 in the tracker | 6 in the tracker |
| Furthest registered phase | Phase 2 | Phase 2 |
| Trials currently active | 0 | 0 |
| Trial sponsors | Lateral Pharma Pty Ltd | NeuroSearch A/S, Boehringer Ingelheim |
| Published trials covered on its page | 7 | 7 |
| Amounts studied in those trials | METAOD001: 25 to 400 micrograms per kilogram, single intravenous doses for Single doses with a 7 day washout METAOD002: 25, 50 and 100 micrograms per kilogram, single intravenous doses for Single doses with a 7 day washout METAOD004: 9, 27 or 54 mg once daily, oral for 7 days As reported on the compound page. Amounts are not comparable between compounds. | SCEPTRE, NCT00148486: NS 2330 0.25, 0.5 or 1.0 mg once daily, oral, or placebo for 14 weeks ADVANS, NCT00148512: NS 2330 0.125, 0.25, 0.5 or 1.0 mg once daily, oral, or placebo, five parallel groups for 14 weeks NCT00153010: Three doses of NS 2330 once daily, oral, or placebo; the doses are not stated in the registry record for 14 weeks As reported on the compound page. Amounts are not comparable between compounds. |
| What is not known | Whether it causes fat loss in a human being at any dose by any route. The 12 week study produced a signal at its lowest dose, the 24 week confirmatory study found no significant difference against placebo, and no third study was ever run. The... | Whether it is cardiovascularly safe, in either direction. No trial has ever measured myocardial infarction, stroke, cardiovascular death or hospitalisation for heart failure on tesofensine. The two year cardiovascular safety study in the planned phase 3 programme was never run, and the longest exposure in... |
Full pages: AOD-9604 and Tesofensine. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
